Ignite Creation Date:
2025-12-25 @ 3:20 AM
Ignite Modification Date:
2026-02-11 @ 1:20 AM
Study NCT ID:
NCT01059305
Status:
TERMINATED
Last Update Posted:
2017-04-04
First Post:
2010-01-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Skin Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Erlotinib | View |
| None | Erlotinib Hydrochloride | View |
| None | OSI-774 | View |
| None | Tarceva | View |
| None | Squamous cell carcinoma of the skin | View |
| None | Aggressive cutaneous squamous cell carcinoma | View |
| None | CSCC | View |
| None | Local surgery | View |
| None | Radiation therapy | View |
| None | Epidermal growth factor receptor | View |
| None | EGFR | View |
| None | Small Molecule Tyrosine Kinase Inhibitor | View |